Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Inovio Pharmaceut…

USUSD
← Allo screener
US:INOLSE:0A43

Inovio Pharmaceuticals Inc (US:INO) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'azienda

Sito web
inovio.com
Relazioni con gli investitori
ir.inovio.com/overview/default.aspx
Settore
Health Care · Biotechnology: Pharmaceutical Preparations
Sede centrale
PLYMOUTH MEETING, United States
Amministratore delegato
Jacqueline E. Shea
Dipendenti
112
Azioni in circolazione
103.4 Mln al 2026-08-10
Flottante
95.79 Mln
Capitalizzazione di mercato
118.91 Mln USD
Insider
0.33%
Investitori istituzionali
46.06%
Settore (SIC)
Pharmaceutical Preparations
FCF
−80.8 Mln USD
Debito
62.8 Mln USD
Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Borse e ticker

BorsaTickerValutaPrezzoTipo
US USA StocksINO principaleUSD1.09 -5.63%azioni ordinarie
LSE London Stock Exchange0A43 IOBUSD1.1919 +0.00%azioni ordinarie

Prezzo su 3 mesi

3M1Y3Y5Y
giorno di rialzo giorno di ribassoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo

Notizie di questa settimana

Nessuna notizia nell'ultima settimana. Ultime notizie: 01.09.2026.

pubblicità

Principali azionisti

DetentoreQuotaAzioniData del rapporto
FMR, LLC8.18%8.45 Mln2026-06-30
Fidelity Securities Fund…6.76%6.99 Mln2026-07-31
Jupiter Topco LLC5%5.17 Mln2026-06-30
Vanguard Capital Managem…3.53%3.65 Mln2026-06-30
Fidelity Securities Fund…3.42%3.54 Mln2026-07-31
Boxer Capital Management…2.75%2.84 Mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.51%2.6 Mln2026-06-30
Adar1 Capital Management…2.07%2.14 Mln2026-06-30
Shaw D.E. & Co., Inc.1.31%1.35 Mln2026-06-30
Two Sigma Investments, L…1.2%1.24 Mln2026-06-30
Eversept Partners, LP1%1.04 Mln2026-06-30
VANGUARD INDEX FUNDS-Van…0.93%963 3252026-06-30
Geode Capital Management…0.78%802 7512026-06-30
Millennium Management Ll…0.77%796 1072026-06-30
Fidelity Concord Street…0.39%398 4002026-07-31
iShares Trust-iShares Mi…0.27%278 2952026-08-31
Bridgeway Funds, Inc.-Ul…0.17%173 0002026-06-30
SHEA JACQUELINE ELIZABET…≈0.11%111 0212026-05-20
Fidelity Concord Street…0.1%104 0052026-07-31
Fidelity Concord Street…0.09%96 1192026-07-31
WEINER DAVID B (Director…≈0.08%87 5922026-02-26
Invesco Exch-Trd Fd. TRT…0.08%85 2652026-08-31
HUMEAU LAURENT M (Office…≈0.05%46 8232026-05-20
KIES PETER D (Chief Fina…≈0.04%43 2292026-05-20
SUMNER MICHAEL JOHN (Off…≈0.04%42 0382026-05-20
BENITO SIMON X (Director…≈0.01%12 1912025-05-21
YARNO WENDY L (Director)≈0.01%10 5122025-05-21
MILLER ANN CALBY M.D. (D…≈0.01%9 8772025-05-21
SHEPARD JAY P. (Director…≈0.01%9 2092025-05-21
DANSEY ROGER D (Director…≈0.01%8 9162025-05-21